Waldenström macroglobulinemia treatment algorithm 2018

Gertz, Morie A.

doi:10.1038/s41408-018-0076-5

Cited by 21 publications

(30 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Las guías internacionales proponen el uso de rituximab asociado a ciclofosfamida y dexametasona, bendamustina, o bortezomib y dexametasona, para la enfermedad sintomática 10,25,26 . Otras consideraciones son preferir uso de inhibidores de proteosoma cuando la enfermedad se presenta con altos niveles de IgM, falla renal o pacientes jóvenes, para evitar el uso de alquilantes y análogos de nucleósidos 8,27 .…”

Section: Discussionunclassified

Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile

et al. 2019

View full text Add to dashboard Cite

Waldenström macroglobulinemia. Experience in 31 patients Background: Waldenström macroglobulinemia (WM) is an uncommon indolent B-cell lymphoma, due to the proliferation of lymphoplasmacytic cells, and secretion of a monoclonal IgM protein. Aim: To evaluate the clinical characteristics, management and results of treatment of patients with WM at a public hospital in Chile. Patients and Methods: Review of medical records of 31 patients aged 43 to 85 years (16 males) with WM diagnosed between 2002 and 2017. Clinical features and survival were recorded. Results: All patients had bone marrow compromise, and 31%, extranodal involvement. According to the International Prognostic Score System for WM (IPSSWM) 16, 58 and 26% were at low, intermediate and high risk, respectively. Twenty-five patients (81%) were treated, 32% with plasmapheresis and 36% with rituximab. Four cases (16%) achieved complete remission. Median follow up was 35 months (range 6-159). Estimated overall survival (OS) at 5 and 10 years was 74% and 53%, respectively. According to IPSSWM, the estimated five-year OS was 80, 92 and 39%, for low, intermediate and high-risk patients, respectively. Conclusions: OS was similar to that reported abroad, except for low risk patients, probably due to the low number of cases and short follow up. An improved survival should be expected with the routine use of immunochemotherapy.

show abstract

Section: Discussionunclassified

Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile

et al. 2019

View full text Add to dashboard Cite

show abstract

“…WM accounts for over 95% of LPL with non-secretory LPL or LPL with non-IgM paraproteins comprising the remainder [ 18 ]. It is a rare disease, with an incidence of 4 per million per year [ 19 ]. While immunoglobulin heavy chain translocation or aneuploidies are not described in WM, up to 50% of cases demonstrate a 6q deletion [ 20 ].…”

Section: Summary Of Who and Imwg (International Myeloma Working Grmentioning

confidence: 99%

“…Symptomatic anaemia, hyperviscosity and immune manifestations are common modes of presentation [ 19 ]. Hyperviscosity is more common in WM than MM due to the higher molecular weight of the IgM pentamer compared to IgG or IgA [ 22 ].…”

Section: Summary Of Who and Imwg (International Myeloma Working Grmentioning

confidence: 99%

Immunoglobulin M Paraproteinaemias

Girard

Soekojo

Ooi

et al. 2020

Cancers

View full text Add to dashboard Cite

Monoclonal paraproteinaemia is an increasingly common reason for referral to haematology services. Paraproteinaemias may be associated with life-threatening haematologic malignancies but can also be an incidental finding requiring only observation. Immunoglobulin M (IgM) paraproteinaemias comprise 15–20% of monoclonal proteins but pose unique clinical challenges. IgM paraproteins are more commonly associated with lymphoplasmacytic lymphoma than multiple myeloma and can occur in a variety of other mature B-cell neoplasms. The large molecular weight of the IgM multimer leads to a spectrum of clinical manifestations more commonly seen with IgM paraproteins than others. The differential diagnosis of B-cell and plasma cell dyscrasias associated with IgM gammopathies can be challenging. Although the discovery of MYD88 L265P and other mutations has shed light on the molecular biology of IgM paraproteinaemias, clinical and histopathologic findings still play a vital role in the diagnostic process. IgM secreting clones are also associated with a number of “monoclonal gammopathy of clinical significance” entities. These disorders pose a novel challenge from both a diagnostic and therapeutic perspective. In this review we provide a clinical overview of IgM paraproteinaemias while discussing the key advances which may affect how we manage these patients in the future.

show abstract

“… 4 , 8 – 9 The presence of polyneuropathy is currently considered an indication to start treatment in smouldering Waldenström macroglobulinemia. 10 …”

Section: Focal Neuropathiesmentioning

confidence: 99%

Peripheral Nervous System Involvement in Lymphoproliferative Disorders

Sabatelli

Laurenti

Luigetti

2018

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Peripheral neuropathies are a vast group of diseases with heterogeneous aetiologies, including genetic and acquired causes. Several haematological disorders may cause an impairment of the peripheral nervous system, with diverse mechanisms and variable clinical, electrophysiological and pathological manifestations. In this practical review, we considered the main phenotypes of peripheral nervous system diseases associated with lymphoproliferative disorders.The area of intersection of neurological and haematological fields is of particular complexity and raises specific problems in the clinical practice of lymphoproliferative disorders. The personal crosstalk between neurologists and haematologists remains a fundamental tool for a proper diagnostic process which may lead to successful treatments in most cases.

show abstract

Waldenström macroglobulinemia treatment algorithm 2018

Cited by 21 publications

References 70 publications

Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile

Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile

Immunoglobulin M Paraproteinaemias

Peripheral Nervous System Involvement in Lymphoproliferative Disorders

Contact Info

Product

Resources

About